Continuing with its thrust in the Cephalosporin market segment, Aurobindo Pharma has just launched its latest molecule CEFPIROME, a 4^th generation Cephalosporin which offers enormous advantages in the spectrum of anti-bacterial treatment, especially in life threatening infections.

Having very recently received the clearance from the respective Drug Control Authorities, Aurobindo Pharma is all set to launch its own brand of CEFPIROME under the trade mark of IV-CEF which would be available in three parenteral dosage forms of 500 mg, 1 gram, and 2 grams and would be packed as vials.

Aurobindo Pharma’s launch of CEFPIROME is a particular milestone in its history of continuing dominance of the Cephalosporin market segment as the drug is the very first in the line of 4^th generation treatment and is the very latest drug in this category. Just two other players in the globe produce the drug.

Aurobindo Pharma’s R&D thrust has already enabled it to become the world’s second largest Cephalosporin producer. The latest successes it met in launching branded formulations like CEFACTAM besides the exciting prospects for IV-CEF makes the management take a bullish view with regards the visibility of revenue flows from this segment.